| 摘要 |
Effective urokinase-type plasminogen activator receptor antogonists have sequences selected from the group AEPMPHSLNFSQYLWYT, AEWHPGLSFGSYLWSKT, AEHTYSSLWDTYSPLAF, AESSLWTRYAWPSMPSY, AELDLWMRHYPLSFSNR, AEWSFYNLHLPEPQTIF, AETLFMDLWHDKHILLT, AEPLDLWSLYSLPPLAM, AESLPTLTSILWGKESV, AESQTGTL-NTLFWNTLR, AESSLWRIFSPSALMMS, AEPALLNWSFFFNPGLH, AEAWFLSNTMKALSARL, AEPTLWQLYQFPLRLSG, AEISFSELMWLRSTPAF, AEWTTSSPPLTQYLWGF, AEMHRSLWEWYVPNQSA, AEIKDEKMGLWDLYSM, AEILNF-PLWHEPLWSTE, AELSEADLWITWFGMGS, AESVQYSKLWKPNTTLA, AEPLSLYQKKTLRTIFAN, AELPRTNPVTAVKNPSF, AEQLNRSIPDLQFSMFN, and AESHIKSLLDSSTWFLP, or active analogs or active portions thereof.
|
